Imatinib has been approved for the treatment of patients with BCR-ABL positive chronic myeloid leukemia (CML) and patients with Kit (CD117)-positive gastrointestinal stromal tumors. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.